The Global Myomectomy Market is expected to grow at a high CAGR of 9.1% during the forecasting period (2022-2029).
Myomectomy is a surgical procedure to remove uterine fibroids. These common non-cancerous growths in the uterus of women at their childbearing age, cause symptoms such as heavy bleeding during the menstrual cycle, increased menstrual cramping, pain in the pelvis or lower back, and swelling enlargement of the abdomen. Myomectomy preserves the chances of women getting pregnant.
The global myomectomy market growth is driven by the rising prevalence of uterine fibroids and the growing demand for the diagnosis and treatment of uterine disorders. The increasing number of patients suffering from uterine fibroids and associated conditions, the growing number of less invasive procedures, and the rising adoption of technologically advanced devices for safe and effective myomectomy procedures are the major factors expected to drive the market.
The growing demand for diagnosis and treatment of uterine disorder will drive the market growth
Uterine fibroids are the most common pelvic tumors in women, occurring globally with a prevalence of 21.4%. About 20% to 80% of women develop fibroids by the time they reach age 50. Fibroids are common in women in their 40s and early 50s. About 80% of African American women will develop fibroids by the age of 50. The increasing female aging population is propelling the growth of the market as the elderly population is more susceptible to gynecological problems, such as hormonal imbalance, abnormal uterine bleeding, and irregular menstrual cycle, which is fueling the demand for the global myomectomy market. Another research study published in 2017, which included approximately 5,000 Italian women with uterine fibroids, showed that 95% of the surgeries performed included women in the age group of 36-55 years. Additionally, a rise in the number of minimally invasive surgical procedures due to fewer complications and reduced hospital stay is anticipated to drive the growth of the market. Technological advancements, such as the rise in the number of robotic and laparoscopic-assisted surgeries to deliver quality and efficient treatment, may also contribute to the growth of the myomectomy market.
The launch of technologically advanced products due to the increasing number of myomectomy procedures for uterine fibroids is likely to boost the market growth. Technological advancements such as the introduction of laparoscopic or robotically assisted myomectomy procedures have shown incisionless surgery with no or minimal side effects for fibroids treatment. As compared to the open abdominal myomectomy surgery, with robotic myomectomy patient experience less blood loss with fewer complication rates, have a shorter hospital stay, and returns to normal activities more quickly. Thus, the use of robots for myomectomy surgery and their several advantages over conventional laparoscopy (open surgery), have been widely accepted and incorporated into the field of reproductive surgery.
The complications associated with myomectomy will hamper the growth of the market
However, myomectomy is associated with hemorrhage, infection, bowel obstruction, adhesion formation, damage to the bowel, bladder, fallopian tube, ureter, wound infection, and wound separation. About 20–25% of patients undergoing myomectomy require another pelvic operation, usually hysterectomy because of recurrence of symptoms. Recurrent myomas are common, especially in patients with multiple myomas. Patients with a solitary myoma have a 27% recurrence rate, and those with multiple myomas have a rate of 59%. Patients undergoing myomectomy should be counseled pre-operatively about these risks and must understand that myomectomy may not be possible.
The impact of the COVID-19 pandemic is significant on the myomectomy market. With the surge of COVID-19 cases across the world, healthcare services diverted their resources toward the patients suffering from COVID-19. Guidelines and recommendations were provided for the management of patients during the pandemic. This resulted in hospitals prioritizing emergency procedures and delaying or postponing elective procedures, such as myomectomy surgery, leading to a backlog of patients waiting for their surgeries for months. A CovidSurg Collaborative study, 2020, estimated that around 28 million operations would be delayed during the peak 12-week disruption due to COVID-19, including 81.7% benign surgeries. With conditions returning to normal, myomectomy procedures are expected to recover gradually.
The abdominal segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)
The abdominal segment, also known as the open type, is considered the classic myomectomy surgery. This procedure is performed by making a small horizontal incision (or a vertical incision for a larger uterus) across the abdomen region of the body. With the rise in the number of patients with uterine fibroids, the demand for myomectomy procedures may also increase. Abdominal myomectomy is the highly performed and preferred type of treatment. A 2017 UK research study published on Gynecological Surgery, Springer Open, involving physician consultants, identifies that nearly 70% of them perform open myomectomy. The open type is preferred based on the size and location of fibroids. Hence, due to such activities across different countries, the number of procedures is expected to grow further over the forecast period.
North America region holds the largest market share of the global myomectomy market
North America dominates the market for myomectomy and is expected to show a similar trend over the forecast period, owing to the rising prevalence of uterine fibroid. A 2018 article published in the American Journal of Obstetrics and Gynecology shows that the prevalence of uterine fibroids was found to be 10% in the United States, with higher occurring rates observed for black women and other ethnic or racial groups. Additionally, according to the World Economic Outlook 2021 by IMF, real GDP is projected to grow by 6.4% in the United States and 5% in Canada. These factors, coupled with high reimbursement rates and government initiatives, contribute to North America occupying the largest share of the overall myomectomy market.
The increased patient pool undergoing hormonal disorders and increasing prevalence of uterine cancer is the key growth driving factor for this regional uterine fibroid treatment market. For instance, in the USA, the prevalence of uterine fibroids was 60% at the age of 35, which increased to more than 80% by the age of 50 years among women.
Also, the adoption of minimally invasive and effective alternatives to open surgeries and technological advancements in devices with an increase in regulatory approvals and favorable reimbursement policies are expected to boost the growth of the myomectomy market in this region.
The myomectomy market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Medtronic PLC, Stryker Corporation, ConMed Corporation, INSIGHTEC Ltd, CooperSurgical Inc., Hologic Inc., Intuitive Surgical Inc., KARL STORZ SE & Co. KG, B Braun, Richard Wolf Medical Instruments among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the Myomectomy Market globally. For instance, in August 2020, Hologic Inc. announced the acquisition of Acessa Health Inc., a privately held company focused on minimally invasive therapies for fibroids. This acquisition is anticipated to strengthen Hologic’s fibroid treatment product portfolio.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical-Surgical Portfolio, and Diabetes Operating Unit.
Veriset Hemostatic Patch: The Veriset patch is designed to address the unmet need for a simple to use, fast, and highly effective hemostatic patch. Medtronic launched the Veriset patch. It is designed to help to achieve hemostasis quickly and consistently, in ~1 minute.
The global myomectomy market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 190 pages.
Get your free sample proposal with a single click!